{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:49:24Z","timestamp":1792442964205,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.10.024","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T17:30:15Z","timestamp":1382203815000},"page":"6011-6021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions"],"prefix":"10.1016","volume":"31","author":[{"given":"Bo-Hyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Stoecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Link-Gelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.024_bib0005","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0010","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0015","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/QAD.0b013e32833d46fd","article-title":"Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.7326\/0003-4819-104-1-79","article-title":"Cost effectiveness of vaccination against pneumococcal pneumonia: an update","volume":"104","author":"Sisk","year":"1986","journal-title":"Ann Int Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0025","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJM198611203152104","article-title":"Efficacy of pneumococcal vaccine in high-risk patients","volume":"315","author":"Simberkoff","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0030","first-page":"1998","article-title":"Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures","author":"French","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0035","unstructured":"Palisade Corporation. @Risk 5.7. Newfield, NY2011."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0040","first-page":"22","article-title":"Centers for disease control and prevention","year":"2010","journal-title":"HIV Surveill Rep"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0045","series-title":"U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999\u20132009 Incidence and Mortality Web-based Report","year":"2013"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0050","unstructured":"Health Resources and Services Administration, U.S. Department of Health & Human Services. Organ Procurement and Transport Network; 2012."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0055","unstructured":"U. S Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0060","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":"The lifetime cost of current human immunodeficiency virus care in the United States","volume":"44","author":"Schackman","year":"2006","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0065","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying) - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0070","first-page":"1","article-title":"United States Life Tables, 2006","volume":"58","author":"Arias","year":"2010","journal-title":"Natl Vital Statist Rep"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0075","unstructured":"Active Bacterial Core Surveillance (ABCs) program. Centers for Disease Control and Prevention; unpublished data; September, 2011."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/infdis\/jir749","article-title":"Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States","volume":"205","author":"Weinberger","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0085","unstructured":"National Center for Health Statistics. National Health Interview Survey. 1957-present. Public-use data file and documentation."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0090","first-page":"2008","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998\u20132003","author":"Teshale","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0095","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ndt\/gfm474","article-title":"Pneumonia in incident dialysis patients\u2014the United States Renal Data System","volume":"23","author":"Guo","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0100","unstructured":"HCUP Nationwide Inpatient Sample (NIS). In: Quality AfHRa, editor. Healthcare Cost and Utilization Project (HCUP). Rockville, MD."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0105","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2013use of 13-valent pneumococcal conjugate vaccine and 23-valent pnuemococcal polysaccharide vaccine","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0110","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","article-title":"23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial","volume":"355","author":"French","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","article-title":"A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults","volume":"362","author":"French","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0120","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1046\/j.1523-1755.2001.0590041382.x","article-title":"Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect","volume":"59","author":"Girndt","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0130","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/319218","article-title":"Adult and adolescent spectrum of HIV disease project. Pneumococcal disease among human immunodeficiency virus\u2013infected persons: incidence, risk factors, and impact of vaccination","volume":"32","author":"Dworkin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/aje\/kwr376","article-title":"Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009","volume":"175","author":"Lu","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0140","first-page":"66","article-title":"Adult vaccination coverage\u2014United States, 2010","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0145","unstructured":"Truven Health Analytics MarketScan Database. Ann Arbor; 1994\u20132010."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0150","unstructured":"BDIPharma. HCPCS Codes & Medicare Payment; 2012."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0155","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2105\/AJPH.89.11.1722","article-title":"The Denver school-based adolescent Hepatitis B vaccination program: a cost analysis with risk simulation","volume":"89","author":"Deuson","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amepre.2006.03.008","article-title":"In\ufb02uenza vaccination: health impact and cost effectiveness among adults aged 50 to 64 and 65 and older","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0165","unstructured":"Bureau of Labor Statistics. Consumer Price Index\u2014All Urban Consumers; 2012."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0170","unstructured":"Khoie T, Tiernan R, deVore N. Prevnar 13\u2122 (PCV13): Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein); 2011."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0175","unstructured":"Winston WL. Simulation Modeling Using @Risk: Brooks\/Cole-Duxbury; 2001."},{"key":"10.1016\/j.vaccine.2013.10.024_bib0180","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.vaccine.2010.05.030","article-title":"Clinical and economic burden of pneumococcal disease in older US adults","volume":"28","author":"Weycker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0185","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/592691","article-title":"Pneumococcal vaccination of elderly adults: new paradigms for protection","volume":"47","author":"Jackson","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0190","doi-asserted-by":"crossref","first-page":"e6879","DOI":"10.1136\/bmj.e6879","article-title":"Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis","volume":"345","author":"RozenBaum","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0195","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.169","article-title":"Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine","volume":"307","author":"Smith","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0200","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.2012.194","article-title":"Prevention of Pneumococcal infection with vaccines","volume":"307","author":"Shapiro","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0205","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/656147","article-title":"A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults","volume":"202","author":"Crum-Cianflone","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0210","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1001\/archinte.160.17.2633","article-title":"Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients","volume":"160","author":"Breiman","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0215","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1086\/520977","article-title":"Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study","volume":"45","author":"Pe\u00f1aranda","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0220","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0272989X02238300","article-title":"A meta-analysis of utility estimates for HIV\/AIDS","volume":"22","author":"Tengs","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0225","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0230","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.22388","article-title":"Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score","volume":"17","author":"\u00c5berg","year":"2011","journal-title":"Liver Transplantat"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/0272989X9701700401","article-title":"Cost-effectiveness of repeat medical procedures: kidney transplantation as an example","volume":"17","author":"Hornberger","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0240","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","article-title":"Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States","volume":"28","author":"Rubin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.024_bib0245","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1057\/jors.1987.45","article-title":"Some results concerning the estimation of Beta distribution parameters in PERT","volume":"38","author":"Farnum","year":"1987","journal-title":"J Opl Res Soc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1301400X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1301400X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T20:53:42Z","timestamp":1539291222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1301400X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":49,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X1301400X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}